Post-marketing Clinical Study of Ipragliflozin -Study to Assess the Efficacy, Safety and Tolerability of Ipragliflozin in Combination With Insulin Preparation in Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Insulin Therapy-

Trial Profile

Post-marketing Clinical Study of Ipragliflozin -Study to Assess the Efficacy, Safety and Tolerability of Ipragliflozin in Combination With Insulin Preparation in Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Insulin Therapy-

Completed
Phase of Trial: Phase IV

Latest Information Update: 13 Jun 2017

At a glance

  • Drugs Ipragliflozin (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Acronyms IOLITE
  • Sponsors Astellas Pharma
  • Most Recent Events

    • 13 Jun 2017 Results presented at the 77th Annual Scientific Sessions of the American Diabetes Association
    • 10 Jun 2017 Biomarkers information updated
    • 15 Jan 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top